Breaking News Instant updates and real-time market news.

TEVA

Teva

$45.40

0.21 (0.46%)

08:06
10/07/16
10/07
08:06
10/07/16
08:06

Teva price target lowered to $57 from $61 at Leerink

Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.

  • 06

    Nov

  • 15

    Nov

TEVA Teva
$45.40

0.21 (0.46%)

09/29/16
OTRG
09/29/16
INITIATION
OTRG
Positive
Teva initiated with a Positive at OTR Global
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Outperform
Teva shares suffering from lack of catalysts, says Wells Fargo
Wells Fargo analyst David Maris attributes the continued slide in Teva (TEVA) shares largely to negative sector news such as the drug pricing debate, fears on generic pricing, and Mylan's (MYL) EpiPen issue, but also thinks the slide has been made worse by Teva's lack of near-term catalysts. Additionally, the ongoing Copaxone generic trial and Teva's recently filed suit against Rimsa's founders over allegedly being misled by the Mexican pharmaceutical company have added to the pressure, Maris noted. Maris acknowledges there may be "no notable catalysts" for the rest of the year for Teva, but he thinks it should be a "robust 2017" for the company and keeps an Outperform rating on the shares.
10/05/16
WELS
10/05/16
NO CHANGE
WELS
Outperform
Teva estimates lowered on generic trends at Wells Fargo
Wells Fargo analyst David Maris lowered his estimates for Teva (TEVA) for this year and next, citing expectations for lower generic sales this year and lower margins in the generic business. Maris lowered his price target range for Teva shares to $60-$61 from $70-73 based on his lower estimates as well as the uncertainty of the environment, but keeps an Outperform rating on shares citing valuation and his belief 2017 should be a better year with several pipeline events for Teva.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.